HealthBeacon SHA

Board/Management Information • Jun 16, 2022

National Storage Mechanism | Additional information

RNS Number : 0579P

HealthBeacon PLC

16 June 2022

HealthBeacon announces appointment of VP of Global Operations and introduction of Green Labs facility in the United States

Dublin, 16 June 2022: HealthBeacon plc, the leading digital therapeutics company that develops products for managing injectable medications for patients in the home, is pleased to announce the appointment of Omar Sosa as Vice President of Global Operations and Green Labs USA.

With 15 years' pharmacy experience and a strong track record in delivering growth, Omar brings a wealth of specialist expertise to HealthBeacon. He has previously held senior roles at Priority Health Care, Aetna Specialty, Oncology Therapeutics Network, Shoppers Drug Mart.

Omar founded Mevesi Inc, a business intelligence and data warehousing company serving the pharmacy industry and served as CEO until it was acquired in 2018. Following its acquisition, Omar worked as a consultant across various healthcare organisations and served as the Chief Technology Officer of Independent Medical Group, a multi-site infectious disease clinic.

In his new role, Omar will oversee HealthBeacon's business operations and as it scales to 100,000 deployed devices by the end of 2023. In addition, Omar will drive the growth of Green Labs facilities, customer care teams, and production and distribution in six countries.

HealthBeacon will introduce its USA Green Labs facility in the United States in Q4 2022. Having launched its first facility in Ireland in partnership with Novartis earlier this year, HealthBeacon Green Labs is a positive step towards addressing the global challenge of sustainably managing patients' waste and supporting pharmaceutical companies to engage in more sustainable waste management practices.

HealthBeacon's smart technology reminds the patient to take their medication and notifies them when their sharps bin is nearing capacity. The full sharps bin is then collected from the patient's home, undergoes a validated washing regime and can then be returned to the patient for re-use, ensuring an environmentally friendly service for patients.

Commenting on the appointment, HealthBeacon CEO, Jim Joyce, said: "This is an important appointment for HealthBeacon and we are delighted to have someone of Omar's calibre on board. Omar will support HealthBeacon's growth plans to bring our proven injection adherence technology to millions of US customers taking critical medications through injection in their homes. As we continue to grow, we are mindful of the impact we want to have as a business on the environment. Ultimately, we want to improve injection adherence in a sustainable way and the introduction of our Green Labs facility in the United States is a key step in doing that."

Omar Sosa commented on his appointment: "I am really excited to begin this role with a company as exciting as HealthBeacon. The organisation has a clear goal in aiming to improve patients' injection adherence globally and I am looking forward to playing a role in that mission. The introduction of the Green Labs facility in Florida later this year also means that we are going to be doing this in a sustainable way in the United States."

For further information, contact:

Enquiries:
HealthBeacon: Laurence Flavin	Company.Secretary@HealthBeacon.com
Goodbody (Euronext Listing Sponsor and Broker): David Kearney	+353 (1) 667 0420
Stephen Kane
Drury (Public Relations):
Billy Murphy	+353 (0) 87 231 3085
Cathal Barry	+353 (0) 87 227 9281

About HealthBeacon

Headquartered in Dublin, HealthBeacon is an Irish digital therapeutics company that develops products for managing injectable medications for patients in the home. The HealthBeacon Injection Care Management System tracks adherence and persistence with medication schedules through the provision of medication management reminders, safe and sustainable sharps disposal devices, educational tools, and artificial intelligence (AI) driven data analytics. The Company operates across Europe, North America and the United Kingdom and employs more than 70 people and has obtained more than 30 design and utility patents. Peer reviewed evidence supports a 19% improvement in therapy persistence by patients and up to 26% improvement in adherence to therapy, which improves clinical outcomes and significantly improves efficiency in health systems. The Company’s mission is to become the world’s leading digital therapeutics platform for injectable medications.

Ends

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

ISEBCGDLLUBDGDU